Home > Blog > ABO Incompatible Kidney Transplant in India (2026): Eligibility, Success Rates, Procedure & Recovery

ABO Incompatible Kidney Transplant in India (2026): Eligibility, Success Rates, Procedure & Recovery

Filters & Insights

Learn how ABO incompatible kidney transplant works in India — eligibility, desensitization, plasmapheresis, recovery, and cost for the patient

A mismatched blood group between donor and recipient no longer rules out a kidney transplant — ABO incompatible (ABOi) transplant uses a pre-treatment process to make it possible.

The recipient undergoes desensitization (rituximab plus plasmapheresis or immunoadsorption) over roughly 1–3 weeks to lower antibody levels before surgery.

A large published Indian study (247 patients) reported patient survival of 97.8% / 93.5% / 93.5% at 1, 3, and 5 years — strong, India-specific data, though outcomes vary by centre and individual case.

ABOi transplant typically costs more than a standard living-donor transplant due to the added desensitization process; indicative international-patient cost is roughly $30,000–$55,000+.

Shifam Health coordinates specialist consultation, hospital selection, donor evaluation planning, visa assistance, and follow-up for international patients.

“My family member wants to donate a kidney, but our blood groups don’t match.” It’s one of the most common — and most stressful — moments in a family’s kidney transplant journey. For years, a blood-group mismatch meant the donor had to be ruled out and the patient went back to the deceased-donor waiting list, often for years on dialysis.

That’s no longer automatically true. ABO incompatible (ABOi) kidney transplantation allows transplantation across blood groups, using a structured medical process to reduce the antibodies that would otherwise attack the donor kidney. It isn’t right for every patient, and it does involve extra preparation — but for many families, it turns a “no” into a realistic “yes.”

This guide walks through how ABOi transplant actually works, who’s eligible, what the desensitization process involves day to day, what the evidence says about outcomes, and what it looks like to pursue this as an international patient in India.

Before you read on: ABOi transplant decisions depend on individual antibody levels, donor and recipient health, and centre-specific protocols. This article is designed to help you ask better questions of a transplant team — not to replace that evaluation.

SEND YOUR medical REPORTS AND GET YOUR CASE REVIEWED BY TOP nephrologist

Can You Receive a Kidney From a Different Blood Group?

Yes, in many cases. ABO incompatible kidney transplant uses a pre-transplant desensitization process — typically rituximab followed by plasmapheresis or immunoadsorption — to lower the recipient’s anti-blood-group antibodies to a safe level before surgery, allowing transplantation across blood groups that would otherwise be rejected.

What Is an ABO Incompatible Kidney Transplant?

Every person has one of four blood groups (A, B, AB, or O), and the body naturally produces antibodies against the blood groups it doesn’t have. In a standard (“ABO compatible”) transplant, donor and recipient blood groups are matched specifically to avoid these antibodies attacking the new kidney.

In an ABO incompatible transplant, the donor and recipient have different blood groups. Historically, this was considered too risky — the recipient’s existing antibodies would attack the donor kidney almost immediately. Advances over the past two decades, particularly in antibody-removal techniques and targeted immunosuppression, have made it possible to safely lower those antibody levels beforehand, opening the door to transplantation that wouldn’t have been possible before.

Factor	ABO Compatible Transplant	ABO Incompatible Transplant
Blood Group	Matched donor and recipient.	Different donor and recipient blood groups.
Pre-transplant Preparation	Standard transplant evaluation.	Evaluation plus desensitization (rituximab and plasmapheresis/immunoadsorption).
Antibody Monitoring	Routine monitoring.	Frequent antibody titer testing before and after surgery.
Additional Cost	No extra desensitization cost.	Higher due to desensitization sessions and monitoring.
Best Suited For	Patients with compatible living donors.	Patients with willing living donors despite blood group mismatch.

Who Is Eligible?

Eligibility depends on both the recipient’s medical condition and the antibody levels involved — not simply on having a willing donor with a different blood group.

Recipient considerations:

End-stage kidney disease requiring transplant, with no medical contraindication to surgery
Baseline anti-blood-group antibody (isoagglutinin) titer within a range the centre’s protocol can safely reduce
Adequate cardiac and overall health to tolerate surgery and desensitization
No active, uncontrolled infection at the time of evaluation

Donor considerations:

Standard living-donor health and kidney function evaluation, same as for compatible transplant
Willingness and medical clearance to proceed as a living donor
A different blood group from the recipient is, by definition, what makes this an ABOi case — it isn’t itself a barrier

Other factors a transplant team will weigh:

Age (evaluated case-by-case rather than against a fixed cutoff)
Previous transplant history, if any
Comorbidities such as diabetes or cardiovascular disease
For international patients: completeness of prior medical records and donor work-up before travel

Very high baseline antibody titers can make desensitization more difficult, longer, or in some cases inadvisable — this is determined by the transplant team based on actual lab results, not something a general guide can predict.

Planning Your Kidney Transplant in India?

Let Shifam Health guide you through every step from hospital selection and cost estimates to medical visa assistance and travel support. Get a free personalised consultation today.

How ABO Incompatible Kidney Transplant Works

Stage	What Happens
Initial Consultation	Recipient and donor evaluation, blood group testing, and baseline antibody titer measurement.
Crossmatch & HLA Typing	Tests donor-recipient compatibility and overall immunological risk.
Desensitization Planning	Target antibody titer (commonly ≤1:8) is set before transplant.
Rituximab Therapy	Usually given 2–3 weeks before desensitization to reduce antibody-producing cells.
Plasmapheresis / Immunoadsorption	Typically 3–6 sessions to remove harmful antibodies from the bloodstream.
Final Pre-transplant Testing	Confirms the antibody titer has reached the target level before surgery.
Kidney Transplant Surgery	Living-donor transplant performed once desensitization goals are achieved.
Post-operative Monitoring	Regular antibody titer and kidney function checks to detect early rejection.

The number of sessions needed varies by patient — published Indian case series report averages around three immunoadsorption procedures to reach target titers, though this depends entirely on the individual’s starting antibody level.

Book Your Free Consultation Today

What Is Plasmapheresis?

Plasmapheresis (also called plasma exchange) is a procedure that filters the blood to remove antibodies, similar in setup to dialysis. Blood is drawn through a line, passed through a machine that separates and removes plasma (which carries the antibodies), and the blood is returned to the body with replacement fluid.

What it involves for the patient:

Each session typically takes a few hours
Performed through a vein, often using a temporary central line for the series of sessions
Patients are usually awake and seated or lying down throughout
A blood thinner is used during the procedure to prevent clotting in the machine

Why it’s needed: It physically lowers the antibody level that would otherwise attack the donor kidney, working alongside rituximab to bring the recipient to a safe transplant threshold.

Possible side effects: Low blood pressure during the session, a tingling sensation (from the blood thinner used), mild fatigue afterward, and a small risk of infection at the line site. Serious complications are uncommon when performed at an experienced centre, but should be discussed directly with your transplant team.

Some centres use immunoadsorption instead of standard plasmapheresis — a more selective technique that removes antibodies using a specialised column rather than removing whole plasma. It’s often associated with fewer sessions and no need for replacement plasma, though it can be more resource-intensive to provide.

Why Rituximab Is Used Before Transplant

Rituximab is a medication that reduces the population of B-cells — the cells responsible for producing antibodies, including the ones that would attack a mismatched donor kidney.

Timing: Typically given as a single dose around 2–3 weeks before the desensitization (plasmapheresis) process begins, giving it time to take effect
Purpose: Reduces the recipient’s capacity to keep producing new antibodies, making plasmapheresis more effective and longer-lasting
Monitoring: Patients are monitored for infusion reactions during administration and for infection risk in the following weeks, since reduced B-cell activity affects immune function
Possible side effects: Infusion-related reactions (managed with pre-medication), increased short-term infection susceptibility, and rare but recognised risks your transplant physician will review with you specifically

What Does the Evidence Say About Success?

Rather than quote a single percentage as if it applies to every patient, it’s worth looking at what’s actually been published. A peer-reviewed study from an Indian transplant centre, reviewing 247 consecutive ABO incompatible kidney transplants performed between 2012 and 2020, reported:

Patient survival: 97.8% at 1 year, 93.5% at 3 years, 93.5% at 5 years (basiliximab induction cohort)
Graft survival: 95.1% at 1 year, 86.6% at 3 years, 85.2% at 5 years

These are strong, real-world numbers from a single Indian centre — and they illustrate that modern ABOi transplant can perform comparably to compatible transplant when done at an experienced programme. That said, published results from one centre don’t guarantee the same outcome at another, and individual factors (starting antibody titer, overall health, donor quality) all affect an individual patient’s prognosis. Internationally, some earlier registry data (such as a widely cited Japanese analysis) found ABOi outcomes slightly behind ABO-compatible transplant — a gap that has narrowed considerably as desensitization techniques have matured. Ask any centre you’re evaluating for their own programme’s published or internal outcomes data.

Book Your Free Consultation Today

Factors that genuinely influence success, beyond the headline numbers:

Hospital and team experience specifically with ABOi protocols
Starting antibody titer and how predictably it responds to desensitization
Donor kidney quality and donor-recipient overall compatibility
Strict medication adherence post-transplant
Early detection and treatment of any rejection episode
Consistency of long-term follow-up

Risks and Possible Complications

Risk	What It Means	How It’s Managed
Antibody-Mediated Rejection	Antibodies attack the transplanted kidney, usually during the first few weeks.	Frequent antibody titer checks, biopsy if needed, and prompt treatment.
Infection	Desensitization and immunosuppressive drugs increase infection risk.	Preventive antibiotics/antivirals and close monitoring.
Bleeding	Plasmapheresis and surgery may increase bleeding risk.	Careful clotting, fluid, and plasma management.
Delayed Graft Function	The transplanted kidney takes longer to function normally.	Supportive care and temporary dialysis if required.
Medication Side Effects	Higher early immunosuppression can cause drug-related complications.	Regular blood tests and medication dose adjustments.

ABOi transplant requires more intensive early monitoring than a standard transplant — this is a genuine trade-off for being able to proceed with a mismatched donor, not a sign that something has gone wrong.

Recovery After ABO Incompatible Kidney Transplant

Phase	What Happens
Hospital Stay (1–2 Weeks)	Kidney function, antibody levels, wound healing, and medicines are closely monitored.
First Month	Frequent follow-ups, antibody tests, and infection prevention.
Three Months	Fewer visits with continued medication and kidney monitoring.
Six Months	Most patients return to normal daily activities.
One Year & Beyond	Routine check-ups and lifelong immunosuppressive medication.

Practical day-to-day points:

Diet: A kidney-friendly diet is introduced early and adjusted over time with a dietitian’s guidance
Medication: Lifelong immunosuppressive therapy, with closer monitoring than compatible transplant in the first several months
Exercise: Gradual return to activity, typically starting with walking within days of surgery
Travel: Most patients need to remain near the transplant centre for an extended period for frequent early monitoring before international travel is advisable
Returning to work: Varies widely by individual and job type — often discussed around the three-month mark, but determined case-by-case

Need Expert Guidance?

Wondering if you’re eligible for an ABO incompatible kidney transplant in India? Share your medical reports with Shifam Health for a free case review, treatment plan, and cost estimate from leading transplant hospitals.

Advantages Compared With Waiting for a Compatible Donor

For many patients, the realistic alternative to ABOi transplant isn’t a quick compatible match — it’s years of additional dialysis while waiting for a deceased-donor kidney or a compatible living donor. ABOi transplant can offer:

A faster path to transplant when a willing living donor is available but mismatched
Avoiding the cumulative health risks of prolonged dialysis
Generally better long-term outcomes than extended dialysis, which is well established in the broader transplant literature
Keeping a known, motivated living donor in the picture rather than relying on uncertain waitlist timing

The trade-off: ABOi transplant requires additional preparation time (typically 1–3 weeks of desensitization), closer early monitoring, and added cost. For patients with a willing but mismatched donor, this is usually weighed against the alternative of an unpredictable wait — a conversation worth having directly with a nephrologist.

Cost Considerations

ABO incompatible transplant generally costs more than a standard living-donor kidney transplant. The added cost comes from:

Plasmapheresis or immunoadsorption sessions (each session has its own cost, and the total varies by how many are needed)
Rituximab and related desensitization medications
Specialised consumables (such as immunoadsorption columns)
Extended hospital stay and more frequent early monitoring
More intensive early-phase immunosuppression and lab testing

Indicative international-patient cost for ABOi kidney transplant in India typically runs $30,000–$55,000 or more, depending on the recipient’s starting antibody titer, the number of desensitization sessions required, and the hospital. This is meaningfully higher than published domestic-facing starting prices, reflecting the standard markup between domestic and international patient pricing — treat it as a planning range, not a quote.

For a full breakdown of standard kidney transplant costs in India, see our [Kidney Transplant Cost in India] guide. Final pricing for your case depends on your specific antibody profile and chosen hospital — request a personalised estimate from Shifam Health.

Why India Is a Leading Destination for ABOi Transplant

India has one of the more developed ABO incompatible transplant programmes globally, with several centres publishing meaningful patient volumes and outcomes data — something not all countries can offer for this specific procedure. Practical reasons international patients consider India include:

Centres with genuine ABOi-specific experience and published outcomes data, not just general transplant capability
Advanced transplant immunology laboratories capable of frequent antibody titer testing, which ABOi protocols depend on
Cost-adaptive approaches (such as immunoadsorption column reuse protocols studied at Indian centres) that have made the technique more accessible without compromising safety, under controlled clinical conditions
English-speaking clinical teams and established international patient support infrastructure
Substantially shorter timelines than the multi-year waitlists for a compatible donor that many patients face at home

This isn’t a claim that India is “the best” globally — it’s a description of why a structurally strong, well-documented ABOi programme exists here, supported by published clinical data rather than marketing claims.

Treatment Journey for International Patients

Medical record review — recipient and (if known) donor records reviewed remotely by our clinical team
Online consultation — discussion with a transplant nephrologist about blood group compatibility, antibody titers, and candidacy
Treatment planning — hospital selection and an indicative cost estimate based on your specific case
Medical visa assistance — documentation support for travel to India
Arrival and pre-transplant work-up — confirmatory testing, crossmatch, baseline antibody titer
Desensitization — rituximab followed by plasmapheresis/immunoadsorption sessions
Transplant surgery
Recovery and close early monitoring, followed by discharge once medically cleared
Remote follow-up — coordinated monitoring once you’ve returned home

Questions to Ask Before Choosing a Hospital

How many ABO incompatible transplants has this specific centre performed, and what are their published or internal outcomes?
Does the hospital have an in-house transplant immunology laboratory for frequent antibody titer testing?
Is 24/7 nephrology and transplant-team coverage available, particularly in the early post-operative weeks?
Is there a dedicated transplant ICU and emergency response capability?
What does long-term, remote-capable follow-up look like once I’ve returned home?
Will I have a single point of contact (transplant coordinator) throughout?

Common Myths About ABO Incompatible Transplant

Myth: A mismatched blood group means transplant is impossible. Fact: With modern desensitization protocols, transplantation across blood groups is now a well-established option at experienced centres.

Myth: ABO incompatible transplants always fail. Fact: Published outcomes from experienced Indian centres show strong patient and graft survival, broadly comparable to standard transplant when performed by an experienced programme. Failure is not the expected outcome.

Myth: Only young patients qualify. Fact: Eligibility depends on overall health, antibody levels, and organ function — not a fixed age cutoff. Both adult and paediatric ABOi transplants are performed in India.

Myth: Recovery is completely different from a standard kidney transplant. Fact: The core recovery process is similar; the main difference is more intensive antibody monitoring in the first few weeks, when rejection risk is highest.

Frequently Asked Questions

Can blood group O donate to blood group A through ABOi transplant?

Yes — ABOi transplant is specifically designed to enable transplantation across mismatched blood groups, including O-to-A and other combinations, following desensitization.

Is ABO incompatible transplant safe?

Published data from experienced centres shows strong safety outcomes, though it does carry a higher early monitoring requirement than standard transplant. Discuss your specific risk profile with a transplant nephrologist.

How long does preparation (desensitization) take?

Typically around 1–3 weeks, depending on the recipient’s starting antibody titer and how it responds to treatment.

Can foreigners undergo ABO incompatible kidney transplant in India?

Yes, several Indian centres with established ABOi programmes accept international patients, supported by international patient coordination services.

Does plasmapheresis hurt?

Most patients describe it as similar to a long blood draw or dialysis session — not typically painful, though some experience tingling from the blood thinner used or mild fatigue afterward.

Is lifelong medication required?

Yes. Immunosuppressive therapy is required for life after any kidney transplant, including ABOi cases.

How often are follow-up visits needed?

Most intensively in the first month (often several times a week), tapering to weekly, then monthly, then every few months over the first year.

What is a “titer,” and why does it matter?

A titer measures the concentration of anti-blood-group antibodies in the blood. Desensitization aims to bring this down to a safe target level (commonly ≤1:8) before and immediately after surgery.

What’s the difference between plasmapheresis and immunoadsorption?

Plasmapheresis removes whole plasma (carrying antibodies) and replaces it with substitute fluid. Immunoadsorption selectively removes antibodies using a specialised column, often requiring fewer sessions and no replacement plasma

How much does ABO incompatible kidney transplant cost in India?

Indicative international-patient cost typically runs $30,000–$55,000 or more, depending on antibody levels, number of desensitization sessions, and hospital. Request a personalised quote based on your case.

Need Guidance for ABO Incompatible Kidney Transplant in India?

A blood-group mismatch with your donor doesn’t have to mean starting over. Shifam Health helps international patients evaluate whether ABO incompatible transplant is the right path, and coordinates every step if it is:

Specialist consultation and medical record review
Hospital shortlisting based on genuine ABOi experience and outcomes
Donor evaluation planning
Transparent treatment planning and cost estimates
Medical visa assistance and travel coordination
Accommodation and interpreter support during treatment
Coordinated post-transplant follow-up after you return home

This guide is intended to help you ask better questions — not to replace a personalised medical evaluation. Get a Free Consultation → to discuss your case with our clinical team, or Book a Free Call → to speak with a patient coordinator directly.

Ready to Take the Next Step?

An ABO incompatible kidney transplant is no longer a barrier to receiving a life-saving kidney. With modern desensitization protocols and experienced transplant teams, many patients with blood group incompatibility achieve outcomes comparable to standard living-donor transplants. Success depends on careful evaluation, antibody management, and treatment at a specialised transplant centre.

Shifam Health helps international patients through every stage of the journey—from reviewing your medical reports and donor compatibility to selecting the right hospital and transplant surgeon in India.

Get Your Personalised Kidney Transplant Assessment